0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > MMP-2

MMP-2

Brief Information

Name:Matrix metalloproteinase-2
Target Synonym:EC:3.4.24.24,Matrix Metallopeptidase 2 (Gelatinase A, 72kDa Gelatinase, 72kDa Type IV Collagenase),MMP-2,MMP2,Matrix metalloproteinase-2,72 kDa gelatinase,Matrix Metallopeptidase 2,CLG4A,TBE-1,Matrix Metalloproteinase 2 (Gelatinase A, 72kDa Gelatinase, 72kDa Type IV Collagenase),Matrix Metalloproteinase 2,Matrix Metalloproteinase-II,72 KDa Type IV Collagenase,Collagenase Type IV-A,Neutrophil Gelatinase,Gelatinase A,EC 3.4.24.24,MMP-II,MONA,CLG4,EC 3.4.24
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
MM2-M52H9 Mouse Mouse MMP-2 (30-460) Protein, His Tag (active enzyme)
MM2-M52H9-structure
MM2-M52H9-sds
ACRO Quality

Synonym Name

MMP2,CLG4,CLG4A,MMP-II,MONA,TBE-1

Background

Matrix metalloproteinase-2 (MMP-2) is also known as 72 kDa type IV collagenase, 72 kDa gelatinase, Gelatinase A and CLG4A, which belongs to the peptidase M10A family. MMP-2 / CLG4A contains 3 fibronectin type-II domains and 4 hemopexin-like domains. MMP-2 is produced by normal skin fibroblasts. MMP-2 cleaves the collagen-like sequence Pro-Gln-Gly-|-Ile-Ala-Gly-Gln. MMP2 involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AQU-005 AQU-005; NMAQU-005; NM-AQU-005 Phase 1 Clinical Aquilus Pharmaceuticals Neuralgia Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken